Exploring Mechanisms and Morphology of QT Interval Prolongation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-27

Study Completion Date

2019-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The projects will try and optimise the risk stratification for patients with Long QT syndrome by investigating how the exposure of physical and acoustic stress will affect the QT-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic QT-prolongation. Furthermore, the project will investigate the effects of Spironolactone on the QT-dynamics tested by "Brisk Standing".

First, patients are tested with known arrhythmic triggers and they are then administered thier normal dose of beta blockers. Hereafter, "Brisk Standing" test is performed and the patients are on Spironolactone for seven days. After seven days treatment the "Brisk Standing" is repeated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

QT Interval in Athletes

NCT05759260

QT Prolongation

COMPLETED

Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy

NCT00753233

Hypertrophic Cardiomyopathy (HCM)

COMPLETED

Long Term Monitoring for Risk of Sudden Death

NCT04124237

Inherited Cardiac Arrhythmias Long QT Syndrome Arrhythmogenic Right Ventricular Cardiomyopathy +2 more

COMPLETED

Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome

NCT02581241

Long QT Syndrome

COMPLETED NA

Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort

NCT03544918

Long QT Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the projects is to try and optimise the risk stratification for patients with Long QT syndrome by investigating how the exposure of physical and acoustic stress will affect the QT-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic QT-prolongation. Furthermore, the project will investigate the effects of Spironolactone on the QT-dynamics tested by "Brisk Standing".

First, patients are tested with known arrhythmic triggers and they are then administered thier normal dose of beta blockers. Hereafter, "Brisk Standing" test is performed and the patients are on Spironolactone for seven days. After seven days treatment the "Brisk Standing" is repeated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Long Qt Syndrome 1-2 Sudden Cardiac Death

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Beta Blockers

With and without Beta Blockers

Group Type EXPERIMENTAL

Beta Blockers

Intervention Type DRUG

With and without Beta Blockers

Spironolactone

With and without Spironolactone

Group Type EXPERIMENTAL

Spironolactone

Intervention Type DRUG

Brisk Standing before and after seven days treatment with Spironolactone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Beta Blockers

With and without Beta Blockers

Intervention Type DRUG

Spironolactone

Brisk Standing before and after seven days treatment with Spironolactone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Verified Long QT syndrome mutation, subtype 1 or 2.
* over 18 years of age

Exclusion Criteria

* Atrioventricular block,
* Left bundle branch block,
* Left ventricular hypertrophy,
* Pace rhythm,
* ST-deviations \>1 mm),
* Left ventricular ejection fraction \<50 % and significant valvulopathy,
* Unstable psychiatric disease
* Unstable cardiovascular disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes